Connect to sites in 20 countries around the world! AZ accelerates medical innovation in Taiwan: Responding to breakpoints in the patient journey and optimizing disease care
The only foreign pharmaceutical company to win the award, how does AZ help local medical innovations connect with the world?
As the world enters the post-epidemic era, the social trend of paying attention to “sustainable development” is in the ascendant. “ESG”, which emphasizes environmental protection, social responsibility and corporate governance, has become an important indicator for evaluating social enterprises. The century-old pandemic has spurred a surge in the pharmaceutical industry, accelerating efforts to help the Internet drive new medical innovations and promote human sustainability.
Among them, AstraZeneca (AZ), the world’s third largest pharmaceutical company, has not only long-term promoted public welfare affairs that respond to the concept of ESG sustainable development, but also created the “A.Catalyst Network International Biomedical Innovation Link Network Plan”. It is a masterpiece that combines innovation and sustainability, and has also become the only foreign pharmaceutical company to win the 2023 Vision “Corporate Sustainability Citizen Award”.
In fact, the “A.Catalyst Network” has brought together more than 20 physical and virtual medical innovation center sites around the world. Through AZ, it has enriched its profound R&D energy and deep insights into the global pharmaceutical market, successfully assisting various countries around the world, including Taiwan. The local medical industry in the region will find more innovative possibilities and solutions to help the world move towards the sustainable development goals set by the United Nations.
When receiving the award, Taiwan AZ President Claudio Longo pointed out that as a global pharmaceutical leader, AZ insists on using the power of science to create a healthier future for all mankind. The biggest challenge currently facing A.Catalyst Network is the healthcare transformation needs faced by various countries in the post-epidemic era. How to provide more equitable medical resources, help respond to various breakpoints in the disease journey, and even use real-world data to optimize medical services and disease management, and ultimately help the local medical industry integrate with the world, are all important issues that need progress. .
Improve the efficiency of COPD diagnosis at the grassroots level and optimize the quality of respiratory disease care
“The Taiwanese government has great expectations for new medical venture capital investment. However, we found that local manufacturers encountered a big pain point, which is that when the new medical start-up industry wants to “go overseas”, they don’t know how to start and who to contact. Find resources!”
Chen Zhengbin, director of Taiwan’s AstraZeneca Medical Academic Division, said that Taiwan’s strong IT strength is its advantage. However, compared with other technology industry categories, countries have highly regulated the healthcare industry, which not only has high entry barriers, but also has its own unique advantages. Unique ecosystem and culture. As a leading multinational pharmaceutical company, AZ combines industry, government, academia, and research resources from more than 20 countries through the “A.Catalyst Network” to build an Ecosystem Network with AZ as a “catalyst” to help countries Biomedical industry innovation can be implemented and developed faster.
A. Catalyst Network Performance Lead Ted Huang pointed out that the implementation of new innovations is still centered on patient care. For example, in Taiwan’s medical ecosystem, front-line grassroots clinics are very important in identifying early-stage chronic obstructive pulmonary disease. (COPD) patients need more effective plans and solutions, such as the introduction of new medical tools such as portable pulmonary function testing devices, which not only help with the early diagnosis of chronic obstructive pulmonary disease, but also improve medical staff’s awareness of pulmonary obstruction. Understand the disease and optimize local medical care.
Huang Zunhan said that compared with local startup accelerator units, A.Catalyst Network has the market experience of multinational pharmaceutical companies, has in-depth insights into the know-how and policy perspectives of the biomedical industry in various countries, and also provides new startups with global experience Vice president-level one-on-one training guidance helps Taiwan’s biomedical innovation industry explore and develop business models and product solutions with greater potential.
Promote Taiwan’s innovative medical experience and introduce patient groups to collaborate and promote prevention and treatment knowledge
“In the post-epidemic era, we are also helping new manufacturers to integrate with medical institutions to collect and analyze data in a more forward-looking manner. Like the lung cancer issue that many Taiwanese people are concerned about, collaborative clinical trials are no longer the only option. A.Catalyst Network It can help introduce more innovative medical materials and even AI computing, and combine it with Taiwan’s relatively progressive health care policy to achieve more effects!”
Chen Zhengbin pointed out that the goal of A.Catalyst Network is not only to introduce foreign medical innovation experience into Taiwan, but also to promote Taiwan’s successful medical innovation and clinical experience overseas, in addition to data collection on lung cancer and asthma care. The “Healthy Lungs and Asthma Shield Project” are all achievements that have been “online”. In addition, as an issue related to breast cancer that affects the health of women, AZ also actively collaborates with patient groups to promote disease awareness and genetic testing and other tools through feedback from patients on their disease journey, making breast cancer prevention and treatment knowledge more visible and universal.
Chen Zhengbin said that on major cancer issues, in addition to expert clinical experience, patient groups’ experience sharing is important data for optimizing the care system. AZ’s data and experience in the country’s early lifting of lockdown will also serve as a basis for cancer screening in Taiwan’s post-epidemic era. Lessons for prevention and treatment. In the future, A.Catalyst Network will continue to combine real-world insights and a transnational medical innovation resource network to push mankind forward on the path of health equality.
Further reading:
Solve the pain points of medical big data! AZ links TriNetX global electronic medical record system to support Taiwan’s integration with international clinical trials
